09/28/18 - 4:00 PM to 5:00 PM
Student Seminar Series: Professor Matthew S. Sigman
Student Seminar Series
Professor Sigman is the Peter J. Christine S. Stang Presidential Endowed Chair of Chemistry at the University of Utah. He earned his bachelor's degree from Sonoma State University, and his doctorate from Washington State University under the tutelage of Professor Bruce Eaton. He was a National Institutes of Health Post-doctoral Fellow at Harvard University, working with Professor Eric Jacobsen. He joined the faculty at the University of Utah in 1999, and was promoted to full professor in 2008. He also was a visiting professor at the Huntsman Cancer Institute at the University of Utah for a year, 2009-2010. Professor Sigman's honors and awards include being elected a Fellow of the American Association for the Advancement of Science, receiving the Arthor C. Cope Scholar Award, Pfizer Award for Creativity in Organic Chemistry, Camille and Henry Dreyfus Teacher Scholar Award, and National Science Foundation CAREER Award. He is an associate editor for the Journal of the American Chemical Society, and on the editorial advisory board for the Journal of Organic Chemistry.
Professor Sigman's research program is focused on the discovery of new practical catalytic reactions with broad substrate scope, excellent chemoselectivity, and high stereoselectivity to access novel medicinally relevant architectures. Researchers in his group believe the best strategy for developing new classes of catalysts and reactions applicable to organic synthesis is using mechanistic insight to guide the discovery process. This allows them to design new reaction motifs or catalysts in which unique bond constructions can be implemented furthering new approaches to molecule construction. An underlying theme to these methodologies is to convert relatively simple substrates into much more complex compounds allowing for access to known and novel pharmacaphores in a modular manner. This provides the researchers with the ability to readily synthesis analogs enabling us to understand the important structural features responsibility for a phenotypic response in a given biological assay. Sigman's researchers are currently engaged in several collaborative projects to evaluate compound collections for various cancer types at the Huntsman Cancer Institute at the University of Utah and are engaged in follow-up investigations to identify improved compounds as well as understanding the mechanism of action. Some of the diverse projects include Pd-catalyzed alkene oxidations, enantioselective heck-type reactions enantioselective catalysis and ligand design, novel diarylmethines as lead compounds for breast cancer therapy, and studies member of the Center for Stereoselective C-H Functionalization.